Prior to joining Augmenix, Pedersen served as a senior healthcare advisor for two healthcare private equity funds: The Gores Group and The Pritzker Group. In addition, he served on the Boards of Directors of medical device companies Clinical Innovations and Therakos. Prior to this, Pedersen was president of the Urology and Women’s Health Division at Boston Scientific.
“I’m looking forward to working closely with our CEO Darin Hammers and the other board members to continue moving this organization forward,” Pedersen said. “It’s an exciting time to be a part of DYSIS as we continue to expand the company and bring our advanced cervical imaging technology to clinicians worldwide.”
Pedersen earned an MBA from The Harvard Graduate School of Business Administration and an AB degree from Princeton University.
“We are excited to have John join our board as we work to make our innovative DYSIS Ultra device the standard of care for colposcopy. He brings a tremendous amount of leadership experience in the medical device field and a proven track record of commercial success,” said Casper Breum of Lundbeckfondon Ventures.
Earlier this year, the American Medical Association (AMA) granted DYSIS Medical a Category I, Current Procedural Terminology (CPT) add-on code specifically for computer aided mapping of the cervix during colposcopy. AMA granted the code with the support of the American College of Obstetricians and Gynecologists. (ACOG). The purpose of CPT is to provide a uniform language that accurately describes medical, surgical and diagnostic services, and thereby serves as an effective means for reliable nationwide communication among physicians and other healthcare providers, patients and third parties. The new CPT code is expected to become effective on Jan. 1, 2021.